AU2003264427A1 - Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same - Google Patents

Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same

Info

Publication number
AU2003264427A1
AU2003264427A1 AU2003264427A AU2003264427A AU2003264427A1 AU 2003264427 A1 AU2003264427 A1 AU 2003264427A1 AU 2003264427 A AU2003264427 A AU 2003264427A AU 2003264427 A AU2003264427 A AU 2003264427A AU 2003264427 A1 AU2003264427 A1 AU 2003264427A1
Authority
AU
Australia
Prior art keywords
kinasae
same
inhibitory activity
drugs containing
isoquinoline derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003264427A
Other languages
English (en)
Inventor
Masayuki Iwakubo
Yuji Okada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kirin Brewery Co Ltd
Original Assignee
Kirin Brewery Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Brewery Co Ltd filed Critical Kirin Brewery Co Ltd
Publication of AU2003264427A1 publication Critical patent/AU2003264427A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2003264427A 2002-09-12 2003-09-12 Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same Abandoned AU2003264427A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002-267077 2002-09-12
JP2002267077 2002-09-12
PCT/JP2003/011733 WO2004024717A1 (ja) 2002-09-12 2003-09-12 キナーゼ阻害活性を有するイソキノリン誘導体およびそれを含む医薬

Publications (1)

Publication Number Publication Date
AU2003264427A1 true AU2003264427A1 (en) 2004-04-30

Family

ID=31986683

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003264427A Abandoned AU2003264427A1 (en) 2002-09-12 2003-09-12 Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same

Country Status (8)

Country Link
US (1) US7615564B2 (ja)
EP (1) EP1550660A1 (ja)
JP (1) JPWO2004024717A1 (ja)
CN (1) CN100383140C (ja)
AU (1) AU2003264427A1 (ja)
CA (1) CA2502583A1 (ja)
HK (1) HK1082249A1 (ja)
WO (1) WO2004024717A1 (ja)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
WO2007000240A1 (en) 2005-06-28 2007-01-04 Sanofi-Aventis Isoquinoline derivatives as inhibitors of rho-kinase
US7470787B2 (en) 2005-07-11 2008-12-30 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
BRPI0614063A2 (pt) 2005-07-26 2011-03-09 Sanofi Aventis derivados de cicloexilamina isoquinolona
AU2006274245B2 (en) 2005-07-26 2011-11-24 Sanofi-Aventis Piperidinyl-substituted isoquinolone derivatives as Rho-kinase inhibitors
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP1932841B1 (en) * 2005-08-30 2014-01-01 Asahi Kasei Pharma Corporation Sulfonamide compound
CA2620818A1 (en) 2005-09-02 2007-03-08 Astellas Pharma Inc. Amide derivatives as rock inhibitors
US7618985B2 (en) 2005-12-08 2009-11-17 N.V. Organon Isoquinoline derivatives
TW200738682A (en) * 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
US7867999B1 (en) 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
KR20080077652A (ko) 2005-12-22 2008-08-25 알콘 리서치, 리미티드 로 키나제-매개 질환 및 증상 치료용 (인다졸-5-일)피라진및 (1,3-디하이드로인돌-2-온)피라진
EP1891958A1 (en) * 2006-08-03 2008-02-27 Universite Pierre Et Marie Curie (Paris Vi) Rho/Rock/PI3/Akt kinase inhibitors for the treatment of diseases associated with protozoan parasites.
US7893088B2 (en) * 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
US20080064681A1 (en) * 2006-09-11 2008-03-13 Hiroyoshi Hidaka Therapeutic agent for treating glaucoma
ES2729424T3 (es) 2006-09-20 2019-11-04 Aerie Pharmaceuticals Inc Inhibidores de Rho cinasa
US20100022517A1 (en) * 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
US8071779B2 (en) * 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
AR064420A1 (es) 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
NZ577981A (en) 2006-12-27 2011-12-22 Sanofi Aventis Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
BRPI0720909A2 (pt) 2006-12-27 2016-11-01 Sanofi Aventis derivados de isoquinolina e isoquinolinona substituídos
JP5318779B2 (ja) 2006-12-27 2013-10-16 サノフイ シクロアルキルアミン置換イソキノリン及びイソキノリノン誘導体
EP2125745B1 (en) 2006-12-27 2017-02-22 Sanofi Cycloalkylamine substituted isoquinolone derivatives
CA2673920C (en) 2006-12-27 2015-03-24 Sanofi-Aventis Cycloalkylamine substituted isoquinoline derivatives
AU2007338408B2 (en) 2006-12-27 2012-07-26 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8415372B2 (en) * 2007-02-27 2013-04-09 Asahi Kasei Pharma Corporation Sulfonamide compound
AU2008220104B2 (en) 2007-02-28 2012-09-27 Asahi Kasei Pharma Corporation Sulfonamide derivative
ES2396795T3 (es) * 2007-07-02 2013-02-27 Asahi Kasei Pharma Corporation Compuesto de sulfonamida y cirstal del mismo
US8455514B2 (en) 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
EP2249837A4 (en) * 2008-01-31 2011-06-15 Univ Monash METHOD FOR TREATING THROMBOEMBOLIC ILLNESSES
JP2011524912A (ja) * 2008-06-18 2011-09-08 インスパイアー ファーマシューティカルズ，インコーポレイティド Ｒｈｏキナーゼ阻害化合物の眼科用製剤
US8158796B2 (en) * 2008-06-18 2012-04-17 Inspire Pharmaceuticals, Inc. Process for the preparation of Rho-kinase inhibitor compounds
KR101607090B1 (ko) 2008-06-24 2016-03-29 사노피 6-치환된 이소퀴놀린 및 이소퀴놀리논
ES2541827T3 (es) 2008-06-24 2015-07-27 Sanofi Isoquinolinas e isoquinolinonas sustituidas como inhibidores de Rho-cinasa
US8524737B2 (en) 2008-06-24 2013-09-03 Sanofi Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives
US8410147B2 (en) * 2008-06-26 2013-04-02 Inspire Pharmaceuticals, Inc. Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds
US8207195B2 (en) * 2008-06-26 2012-06-26 Inspire Pharmaceuticals, Inc. Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds
US8299096B2 (en) 2008-06-26 2012-10-30 Inspire Pharmaceuticals, Inc. Method for treating pulmonary diseases using rho kinase inhibitor compounds
US20100008968A1 (en) * 2008-06-26 2010-01-14 Lampe John W Method for treating cardiovascular diseases using rho kinase inhibitor compounds
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
CA2737738A1 (en) * 2008-09-18 2010-03-25 Astellas Pharma Inc. Heterocyclic carboxamide compounds
EP2400969A4 (en) * 2008-12-04 2012-05-16 Inspire Pharmaceuticals Inc METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITORY COMPOUNDS
ES2672624T3 (es) 2009-05-01 2018-06-15 Aerie Pharmaceuticals, Inc. Inhibidores de mecanismo doble para el tratamiento de enfermedades
EP2628482A1 (en) 2012-02-17 2013-08-21 Academisch Medisch Centrum Rho kinase inhiitors for use in the treatment of neuroblastoma
FI3811943T3 (fi) 2013-03-15 2023-04-14 Aerie Pharmaceuticals Inc Yhdiste käytettäväksi silmäsairauksien hoidossa
CN105085478B (zh) * 2014-04-28 2019-04-12 南京明德新药研发股份有限公司 异喹啉磺胺衍生物及其药物组合物和制药用途
WO2017064119A1 (en) 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
EP4088719A1 (en) 2015-10-13 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
CN108601355B (zh) 2015-11-17 2021-03-30 爱瑞制药公司 制备激酶抑制剂及其中间体的方法
CN109640966A (zh) 2016-08-31 2019-04-16 爱瑞制药公司 眼用组合物
CA3057872A1 (en) 2017-03-31 2018-10-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US20210292766A1 (en) 2018-08-29 2021-09-23 University Of Massachusetts Inhibition of Protein Kinases to Treat Friedreich Ataxia
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0956865T4 (da) * 1996-08-12 2010-11-22 Mitsubishi Tanabe Pharma Corp Medikamenter omfattende Rho-kinaseinhibitor
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same

Also Published As

Publication number Publication date
US20060167043A1 (en) 2006-07-27
CA2502583A1 (en) 2004-03-25
CN1694879A (zh) 2005-11-09
CN100383140C (zh) 2008-04-23
JPWO2004024717A1 (ja) 2006-01-05
HK1082249A1 (en) 2006-06-02
US7615564B2 (en) 2009-11-10
WO2004024717A1 (ja) 2004-03-25
EP1550660A1 (en) 2005-07-06

Similar Documents

Publication Publication Date Title
AU2003264427A1 (en) Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same
AU2003257666A1 (en) COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME
AU2003254950A1 (en) Peptides and drugs containing the same
AU763356C (en) Fused-ring compounds and use thereof as drugs
AU2223201A (en) Quinoline and quinazoline derivatives and drugs containing the same
HK1086830A1 (en) Heterocyclic compounds and antitumor drugs containing the same as the active ingredient
AU2002306269A1 (en) N-arylphenylacetamide derivatives and pharmaceutical composition containing the same
IL165986A0 (en) Isoquinoline and quinazoline derivatives and pharmaceutical compositions containing the same
HUP0401648A3 (en) 6-hydroxy isoflavon compounds, their derivatives and medicaments involving the same
HUP0002353A3 (en) 1-cycloalkyl-1,8-naphthyridin-4-one derivatives with phoshodiesterase iv inhibitory activity and pharmaceutical compositions containing them
AU2003227712A1 (en) Tetrahydroisoquinoline derivatives
AU2003235956A1 (en) Quinazoline derivative and medicine
AU6475100A (en) Novel anilide derivatives or salts thereof and drugs containing the same
AU2003264406A1 (en) Drug or cosmetic
AU2003288248A1 (en) Dihalo-allyloxy-phenol derivatives having pesticidal activity
AU2001274535A1 (en) Hydroxyformamidine derivatives and medicines containing the same
PL349133A1 (en) Benzamide derivatives and drugs containing the same
AU2003281698A1 (en) 1-phenylpiperidin-3-one derivatives and processes for the preparation thereof
AUPQ462299A0 (en) Pyrazolopyridine compound and pharmaceutical use thereof
AU2002253441A1 (en) Medicaments containing glycerophosphoinositol-4-phosphate derivatives
AU2002308105A1 (en) Benzoaxathiepin derivatives and their use as medicines
AU2003248091A1 (en) Indole derivatives and drugs containing the same
AU5557300A (en) Bafilomycin derivatives with anticancer activity
AU2002323746A1 (en) Novel amine derivative having human beta-tryptase inhibitory activity and drugs containing the same
AU2003252357A1 (en) Sphingosinoids and external preparations for skin containing the same

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase